UCB Expands to Canada
Under the auspices of the 2006 Belgian Economic Trade Mission to Canada, H.R.H. Prince Philippe of Belgium officially inaugurated UCB Pharma Canada at a ceremony held in Toronto. On this occasion UCB Pharma Canada shared its plans for growth in Canada. Research at UCB is focused in the areas of central nervous system disorders, immune and inflammatory disorders, allergy and respiratory diseases, as well as oncology. Based in Burlington, Ontario, UCB Pharma Canada shall endeavor to bring to Canadian patients treatment options that will help alleviate their often-debilitating conditions and provide them a better quality of life.
A key priority for UCB Pharma Canada will be to secure regulatory approval for UCB's new biotherapeutic agent CIMZIATM (certolizumab pegol). Phase III clinical trial results for CIMZIATM in the treatment of Crohn's Disease have encouraged a recent global expansion at UCB, of which the inauguration of its Canadian affiliate is a key element.
"Canada has one of the highest incidences of inflammatory bowel disease in the world," said William Robinson, Executive Vice President, Global Operations, UCB. "Approximately one in 200 Canadians has, or is affected, by Crohn's disease or ulcerative colitis. We hope that CIMZIATM will provide an effective, safe and convenient treatment option to the thousands of Canadians who suffer this relapsing-remitting, cruel disease."
Other news from the department business & finance
